Genprex

Tagged: gene therapy

National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex

Grant to fund ongoing preclinical research for important proof-of-principle non-human studies in preparation for human gene therapy clinical trials

Read More

Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes

Genprex signed an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S, or 9 percent of the U.S. population.

Read More

Genprex’s Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support

AUSTIN, Texas & CAMBRIDGE, Mass.— (October 7, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage company and leader in gene therapy using non-viral vector transfection delivery, wishes to draw attention to additional research in the field validating non-viral vector delivery as the next evolution in gene therapy.

A recently published paper by researchers in Australia, Spain and Austria supports the belief that non-viral delivery could be safer for patients than viral vectors and could speed up the production time while reducing the costs of production….

Read More

Genprex is Defining a New Immunogene Therapy that Could Change the Course of Cancer

Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients, is raising the standard in cancer treatment by developing what it calls an “immunogene therapy,” which harnesses the power of immunotherapy’s immunomodulation through the delivery of a gene therapy.

Gene therapies and immunotherapies are two different types of treatment….

Read More

Pfizer’s Half-Billion-Dollar Manufacturing Facility Demonstrates Commitment to Gene Therapy

Pfizer recently announced its plans to invest $500 million into its Sanford gene therapy manufacturing operations. This expansion would create 300 new jobs, and Pfizer’s biopharmaceuticals group president noted the company “passionately believes in gene therapy.”

This passion for gene therapy, which is seemingly shared with other large biopharma companies, is leading to substantial commitments of resources to gene therapy….

Read More

Big Excitement in Gene Therapy at ASGCT 2019

Earlier this month, Genprex’s President and Chief Operating Officer, Julien Pham attended the American Society of Gene & Cell Therapy’s 22ndAnnual Meeting in Washington, D.C., which brings together industry professionals committed to advancing knowledge, awareness and education of gene and cell therapy. This meeting serves as a catalyst to transform medicine by advancing gene and cell therapies to benefit patients and society….

Read More

How Genprex Differs From “Traditional” Gene Therapy Approaches

Gene therapy is a big and trending topic in the world of medicine and has recently been making headlines as large pharmaceutical companies have been ramping up acquisitions of gene therapy companies. So how exactly does gene therapy work? There are a couple of “traditional” approaches to this generally newer treatment option for rare diseases and cancer….

Read More

IASLC 2019: Bringing Together Collaboration, Science and Hope for the Future

Last month, Genprex’s President and Chief Operating Officer, Julien Pham, attended the IASLC 2019 Targeted Therapies of Lung Cancer Meeting in Santa Monica, California. This meeting brought together a variety of key players working on the newest therapies for lung cancer including researchers, oncologists, physicians, patient advocacy groups and even clinical-stage companies, such as Genprex….

Read More